Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (10)
Type
(
1 selected
)
Type
Guidance (295)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (6)
Medical technologies guidance (7)
Technology appraisal guidance (280)
Apply filters
Showing 101 to 110 of 295
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]
Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]
Technology appraisal guidance
Galcanezumab for migraine TS ID 10663
Technology appraisal guidance
Gantenerumab for treating early Alzheimer's disease TS ID 10668
Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]
Technology appraisal guidance
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312
Technology appraisal guidance
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [TS ID 12050]
Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Technology appraisal guidance
Govorestat for treating classic galactosemia in people 2 to 65 years TS ID 12071
Technology appraisal guidance
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]
Technology appraisal guidance
Previous page
1
…
9
10
Current page
11
12
13
…
30
Page
11
of
30
Next page
Results per page
10
25
50
All
Back to top